Mykronor (Noradrenaline Tartrate)

Noradrenaline tartrate acts as an agonist at alpha‑1 adrenergic receptors, causing peripheral vasoconstriction, and at beta‑1 receptors, modestly increasing heart rate and contractility. This dual action elevates systemic vascular resistance and cardiac output, helping restore adequate tissue perfusion during shock.

The dose of Mykronor is individualized by the treating physician based on the patient’s hemodynamic status, target blood pressure, and response to therapy. Clinicians typically start with a low infusion rate and titrate upward while continuously monitoring vital signs.

Safety data for noradrenaline tartrate in pregnancy and lactation are limited. The product is generally reserved for life‑threatening situations where benefits outweigh potential risks, and its use should be decided by a qualified healthcare professional.

To order Mykronor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mykronor (noradrenaline) primarily provides potent alpha‑1 mediated vasoconstriction with modest beta‑1 activity, making it effective for severe hypotension. Dopamine has dose‑dependent effects, including renal vasodilation at low doses and stronger beta‑1 stimulation at moderate doses, but may cause more tachyarrhythmias. Choice depends on the clinical scenario and physician preference.

Mykronor must be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The vial should be kept in its original packaging, and the solution should not be shaken. Prior to use, inspect for particulate matter and ensure the correct diluent is used according to the product label.

Mykronor is administered intravenously, usually via a dedicated infusion line. The drug is diluted in an appropriate compatible solution and infused under continuous hemodynamic monitoring. Dosage is titrated to achieve target blood pressure while observing for adverse effects.

Serious risks include severe hypertension, cardiac arrhythmias, myocardial ischemia, and tissue necrosis if the drug extravasates from the vein. These complications require immediate recognition and intervention, such as adjusting the infusion rate, providing anti‑arrhythmic therapy, or managing local tissue injury.

Mykronor is contraindicated in patients with known hypersensitivity to noradrenaline or any excipients in the formulation. Caution is advised in individuals with severe peripheral vascular disease, uncontrolled hypertension, or those receiving MAO inhibitors, as the drug may exacerbate these conditions.